远大医药(00512.HK) 公布,集团用于诊断前列腺癌的创新在研放射性核素偶联药物TLX591-CDx在内地进行的III期临床试验,近日已完成全部患者入组给药,并计划于今年内递交新药上市申请,这是集团在核药抗肿瘤诊疗领域的又一次重要研发进展。集团享有该产品在内地、香港、澳门及台湾地区的独家开发及商业化权益。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-12 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.